Cargando…

PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?

SIMPLE SUMMARY: Melanomas with homologous recombination DNA damage repair pathways represent a subset of melanoma that may benefit from PARP inhibitors and immunotherapy. PARP inhibitors have an established role in treating cancers with underlying BRCA mutation through synthetic lethality; however,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, Wei Yen, Brown, Lauren J., Reid, Lee, Joshua, Anthony M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464708/ https://www.ncbi.nlm.nih.gov/pubmed/34572747 http://dx.doi.org/10.3390/cancers13184520

Ejemplares similares

Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors
por: Lim, Joline S. J., et al.
Publicado: (2017)

PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers
por: Collet, Laetitia, et al.
Publicado: (2022)

New treatment option for ovarian cancer: PARP inhibitors
por: Meehan, Robert S., et al.
Publicado: (2016)

Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use
por: Abbotts, Rachel, et al.
Publicado: (2022)

PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
por: Min, Ahrum, et al.
Publicado: (2020)

Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer
por: Yordanova, Mariya, et al.
Publicado: (2021)

Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers
por: Alhusaini, Abdullah, et al.
Publicado: (2021)

PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities
por: Sim, Hao-Wen, et al.
Publicado: (2022)

Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance
por: Kim, Dae-Seok, et al.
Publicado: (2021)

Is autophagy induction by PARP inhibitors a target for therapeutic benefit?
por: ELSHAZLY, AHMED M., et al.
Publicado: (2022)

Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
por: Yuan, Yuan, et al.
Publicado: (2011)

Targeting GPCRs and Their Signaling as a Therapeutic Option in Melanoma
por: Raymond, Jérémy H., et al.
Publicado: (2022)

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
por: Wang, Luyao, et al.
Publicado: (2017)

Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer
por: Franchet, Camille, et al.
Publicado: (2021)

PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues
por: Murthy, Pooja, et al.
Publicado: (2019)

PARP inhibitors: the race is on
por: Brown, Jessica S, et al.
Publicado: (2016)

Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
por: Jang, Albert, et al.
Publicado: (2020)

Emerging Therapeutic Options for the Management of COPD
por: Reid, Debra J., et al.
Publicado: (2013)

Expanding the potential therapeutic options of hemoperfusion in the era of improved sorbent biocompatibility
por: Damianaki, Aikaterini, et al.
Publicado: (2023)

Reverse the Resistance to PARP Inhibitors
por: Kim, Yevgeniy, et al.
Publicado: (2017)

Advances and perspectives of PARP inhibitors
por: Yi, Ming, et al.
Publicado: (2019)

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
por: Keung, Man Yee T., et al.
Publicado: (2019)

Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options
por: Garg, Vikas, et al.
Publicado: (2023)

Role of Biomarkers in the Development of PARP Inhibitors
por: Ganguly, Bratati, et al.
Publicado: (2016)

PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
por: Jonuscheit, Stephanie, et al.
Publicado: (2021)

Aromatase inhibitors in men: effects and therapeutic options
por: de Ronde, Willem, et al.
Publicado: (2011)

PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
por: Gonçalves, Anthony, et al.
Publicado: (2020)

PARP inhibitors: current status and implications for anticancer therapeutics
por: Usmani, Hadi, et al.
Publicado: (2013)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

An update on PARP inhibitors for the treatment of cancer
por: Benafif, Sarah, et al.
Publicado: (2015)

PARP Inhibitors Resistance: Mechanisms and Perspectives
por: Giudice, Elena, et al.
Publicado: (2022)

PARP Inhibitors in Breast and Ovarian Cancer
por: Wang, Samuel S. Y., et al.
Publicado: (2023)

Advances in PARP Inhibitors for Prostate Cancer
por: Tisseverasinghe, Steven, et al.
Publicado: (2023)

Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches
por: Dilmac, Sayra, et al.
Publicado: (2023)

PARP inhibitors in metastatic prostate cancer
por: Taylor, Amy K., et al.
Publicado: (2023)

RAC1 Activation as a Potential Therapeutic Option in Metastatic Cutaneous Melanoma
por: Colón-Bolea, Paula, et al.
Publicado: (2021)

Morphological aspects and therapeutic options in melanoma: a narrative review of the past decade
por: Tinca, Andreea Cătălina, et al.
Publicado: (2023)

A decade of clinical development of PARP inhibitors in perspective
por: Mateo, J, et al.
Publicado: (2019)

PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites
por: Lin, Xiaohui, et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
por: Bruin, Maaike A. C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mrnu52f5hq34g3gqlpqrcgqqj3